REG - Arecor Therapeutics - Collaboration with global pharmaceutical partner

Arecor TherapeuticsAnnouncement

26/03/2025 07:16

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250326:nRSZ1482Ca&default-theme=true

RNS Number : 1482C  Arecor Therapeutics PLC  26 March 2025

Arecor Therapeutics plc

("Arecor" or the "Company")

 

ARECOR ENTERS COLLABORATION WITH MAJOR GLOBAL PHARMACEUTICAL PARTNER

 

-      Collaboration will leverage Arestat(TM) to develop a novel
formulation of partner's proprietary product with enhanced properties

-      Work will be fully funded by partner

 

Cambridge, UK, 26 March 2025: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, announces that it has signed a formulation study agreement with a major
global pharmaceutical partner.

 

Under the terms of the agreement, Arecor will use its proprietary formulation
technology platform, Arestat™, to develop a novel formulation of the
partner's proprietary product with enhanced properties. The partner company
will fully fund the formulation work with the potential for future license
opportunities to follow.

 

Sarah Howell, Chief Executive Officer of Arecor, said: "Arecor continues to
partner with the world's leading pharmaceutical companies, which is testament
to our leadership position in the field of drug delivery and formulation
innovation and further validates the potential of our proprietary technology
platform, Arestat™ to enable enhanced formulations of partners' proprietary
products which would otherwise be unachievable."

 

This announcement contains inside information for the purposes of the
retained UK version of the

EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

 

 

For more information, please contact:

 

 Arecor Therapeutics plc                                 www.arecor.com
 Dr Sarah Howell, Chief Executive Officer                Tel: +44 (0) 1223 426060

                                                         Email: info@arecor.com (mailto:info@arecor.com)
 David Ellam, Chief Financial Officer                    Tel: +44 (0) 1223 426060

                                                         Email: info@arecor.com (mailto:info@arecor.com)

 Singer Capital Markets Advisory LLP (NOMAD and Broker)
 Phil Davies, Sam Butcher                                Tel: +44 (0) 20 7496 3000

 ICR Healthcare
 Chris Gardner, David Daley, Lindsey Neville             Tel: +44 (0) 20 3709 5700

                                                         Email: arecor@icrhealthcare.com (mailto:arecor@icrhealthcare.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio. For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRKZGZFMKZGKZZ